An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)

Trial Profile

An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2017

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions; Registrational
  • Acronyms LEOPARD
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 12 May 2017 Results published in the Journal of Urology
    • 20 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 01 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top